HighTower Advisors
RLAY icon

HighTower Advisors’s Relay Therapeutics RLAY Stock Holding History

HighTower Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$195K Sell
10,431
-307
-3% -$4.46K ﹤0.01% 3549
2026
Q1 		$107K Buy
+10,738
New +$96.1K ﹤0.01% 3629
2025
Q3 		– Sell
-10,320
Closed -$35.7K – 4023
2025
Q2 		$35.7K Sell
10,320
-236,856
-96% -$705K ﹤0.01% 3578
2025
Q1 		$648K Buy
247,176
+47,433
+24% +$186K ﹤0.01% 2268
2024
Q4 		$823K Buy
199,743
+44,823
+29% +$244K ﹤0.01% 2105
2024
Q3 		$1.1M Sell
154,920
-148,425
-49% -$1.11M ﹤0.01% 1884
2024
Q2 		$1.98M Buy
303,345
+56,054
+23% +$383K ﹤0.01% 1459
2024
Q1 		$2.06M Buy
247,291
+34,500
+16% +$337K ﹤0.01% 1422
2023
Q4 		$2.34M Sell
212,791
-72,552
-25% -$612K ﹤0.01% 1353
2023
Q3 		$2.4M Buy
+285,343
New +$3.07M ﹤0.01% 1281
2022
Q3 		– Sell
-17,941
Closed -$302K – 3358
2022
Q2 		$302K Buy
+17,941
New +$385K ﹤0.01% 2359

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

HighTower Advisors's RLAY Position: Q2 2026 in Review

HighTower Advisors reduced its Relay Therapeutics (RLAY) stake by 2.9% in Q2 2026, selling an estimated $4.46K and leaving 10,431 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #3549.

HighTower Advisors first reported a position in RLAY in Q2 2022 and has held it in 11 quarters since. The position peaked at $2.4M in Q3 2023. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • HighTower Advisors held 10,431 shares of Relay Therapeutics worth $195K as of Q2 2026.
  • HighTower Advisors sold 307 Relay Therapeutics shares in Q2 2026, an estimated $4.46K.
  • Relay Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3549 holding.
  • HighTower Advisors first reported a position in Relay Therapeutics in Q2 2022 and has held it in 11 quarters since.
  • HighTower Advisors's Relay Therapeutics position peaked at $2.4M in Q3 2023.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.